CIK 0001231457
- Non-accelerated filer
- Smaller reporting company
- Emerging growth company
GENELUX Corp
Sign in to watch- Ticker
- GNLX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- Phone
- +1 805-267-9889
- Business address
- 2625 TOWNSGATE ROAD, SUITE 230, WESTLAKE VILLAGE, CA, 91361
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $155,693
- in 6 filings
Net −$155,693. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2023-09-26 | Szalay Aladar 10% owner | Sale | −9,600 | $24.51 | $235K | 1,530,723 |
| 2023-09-26 | Yu Yong VP, Clinical Trial Operations | Exercise or conversion | +5,200 | $6.00 | $31K | 111,335 |
| 2023-09-26 | Yu Yong VP, Clinical Trial Operations | Sale | −1,883 | $22.54 | $42K | 109,452 |
| 2023-09-26 | Yu Yong VP, Clinical Trial Operations | Sale | −1,114 | $23.51 | $26K | 108,338 |
| 2023-09-26 | Yu Yong VP, Clinical Trial Operations | Sale | −2,203 | $24.46 | $54K | 106,135 |
| 2023-09-26 | Yu Yong VP, Clinical Trial Operations | Exercise or conversion · Stock Option (right to buy) | −5,200 | 218,053 | ||
| 2023-09-25 | Szalay Aladar 10% owner | Sale | −3,947 | $24.82 | $98K | 1,569,039 |
| 2023-09-25 | Szalay Aladar 10% owner | Sale | −5,511 | $25.75 | $142K | 1,563,528 |
| 2023-09-25 | Szalay Aladar 10% owner | Sale | −1,900 | $26.60 | $51K | 1,561,628 |
| 2023-09-25 | Szalay Aladar 10% owner | Sale | −1,100 | $27.81 | $31K | 1,560,528 |
| 2023-09-22 | Szalay Aladar 10% owner | Sale | −4,421 | $26.88 | $119K | 1,577,607 |
| 2023-09-22 | Szalay Aladar 10% owner | Sale | −4,621 | $27.76 | $128K | 1,572,986 |
| 2023-09-21 | Szalay Aladar 10% owner | Sale | −2,871 | $27.89 | $80K | 1,586,706 |
| 2023-09-21 | Szalay Aladar 10% owner | Sale | −4,678 | $28.82 | $135K | 1,582,028 |
| 2023-09-20 | Yu Yong VP, Clinical Trial Operations | Exercise or conversion | +6,000 | $6.00 | $36K | 112,135 |
| 2023-09-20 | Yu Yong VP, Clinical Trial Operations | Sale | −6,000 | $27.96 | $168K | 106,135 |
| 2023-09-20 | Yu Yong VP, Clinical Trial Operations | Exercise or conversion · Stock Option (right to buy) | −6,000 | 223,253 | ||
| 2023-09-20 | Ryder Sean General Counsel | Exercise or conversion | +10,000 | $6.00 | $60K | 10,572 |
| 2023-09-20 | Ryder Sean General Counsel | Sale | −10,000 | $30.00 | $300K | 572 |
| 2023-09-20 | Ryder Sean General Counsel | Exercise or conversion · Stock Option (right to buy) | −10,000 | 140,000 |
Page 12 of 16 · 315 trades